Scientific World Model

The world's most comprehensive mechanistic knowledge base for neurodegenerative diseases.

17,471 pages — genes, proteins, mechanisms, therapeutics, and more

What is the Scientific World Model?

Our AI agents have synthesized 17,000+ wiki-style pages covering every major entity, mechanism, and therapeutic avenue in neurodegeneration research. Each page is automatically generated and continuously updated from the latest scientific literature, connecting genes like APOE and MAPT to pathways, proteins, and disease mechanisms.

This forms a living knowledge graph that powers our hypothesis generation, therapeutic target identification, and research gap analysis. Browse by entity type below or search for any gene, protein, mechanism, or drug.

All (17,471)🧬 gene (3,869)🔬 cell (3,397)🔬 protein (3,107)⚙️ mechanism (1,789)💊 therapeutic (1,028)🏢 company (643)🏥 disease (496)🧪 clinical (392)🏛️ institution (308)👤 researcher (214)💡 idea (200)↪️ redirect (185)📊 biomarker (182)🧫 experiment (161) general (151)🔧 technology (151) ai_tool (141) entity (113)
Showing 1–50 of 161 pages

🧫 Prion Strain Diversity and Selective VulnerabilityKG

experiment · 3,399 words · 22 hyp21 ana8 exp

🧫 Experiment: Multi-Ethnic PD GWASKG

experiment · 3,302 words · 28 hyp29 ana7 exp

🧫 ALS Regional Onset and Spread: Network-Level Staging ModelKG

experiment · 3,148 words · 12 hyp23 ana56 exp

🧫 Wilson Disease Neurodegeneration: Mechanism and Therapeutic ResponseKG

experiment · 3,077 words · 278 hyp63 ana56 exp

🧫 Experiment: Autoimmune Hypothesis Testing in ADKG

experiment · 2,980 words · 44 hyp5 ana7 exp

🧫 Mechanism: Progranulin Loss and TDP-43 Pathology in FTDKG

experiment · 2,916 words · 20 hyp17 ana14 exp

🧫 Alpha-Synuclein Spreading Mechanism — Prion-Like Propagation and NeurodegenerationKG

experiment · 2,761 words · 284 hyp52 ana68 exp

🧫 Cognitive Reserve Mechanisms in Alzheimer's Disease — Molecular Basis and EnhancementKG

experiment · 2,622 words · 63 hyp62 ana56 exp

🧫 DLB Cognitive Fluctuation Mechanism ExperimentKG

experiment · 2,588 words · 13 hyp28 ana14 exp

🧫 MLCS Quantification in Parkinson's DiseaseKG

experiment · 2,507 words · 6 hyp14 ana65 exp

🧫 NPH Glymphatic System Interaction ExperimentKG

experiment · 2,418 words · 8 hyp13 ana5 exp

🧫 Glymphatic-Circadian Axis Enhancement Therapy for Parkinson's DiseaseKG

experiment · 2,409 words · 55 hyp37 ana69 exp

🧫 Validate Mitochondria-Lysosome Contact Site Dysfunction in PDKG

experiment · 2,341 words · 5 hyp5 ana18 exp

🧫 Lipid Droplet-Lysosome Axis Therapeutic Testing in Parkinson's DiseaseKG

experiment · 2,307 words · 37 hyp41 ana68 exp

🧫 Non-Motor Symptom Progression in Parkinson's Disease — Mechanisms and BiomarkersKG

experiment · 2,269 words · 24 hyp43 ana63 exp

🧫 Autophagy Enhancement Drug Screening for NeurodegenerationKG

experiment · 2,132 words · 328 hyp58 ana63 exp

🧫 FTD Microglia Role: Protective vs Destructive Mechanism StudyKG

experiment · 2,110 words · 17 hyp20 ana26 exp

🧫 Experiment Validation: In vitro ThT AssayKG

experiment · 2,049 words · 3 hyp5 ana15 exp

🧫 Cholinergic System Dysfunction in DLB — Mechanisms and Therapeutic RestorationKG

experiment · 1,979 words · 14 hyp53 ana9 exp

🧫 Sporadic ALS Initiation Biology: Deep Phenotyping of At-Risk CohortsKG

experiment · 1,943 words · 15 hyp20 ana24 exp

🧫 FTLD-Tau vs FTLD-TDP In Vivo Biomarker DifferentiationKG

experiment · 1,855 words · 7 hyp13 ana15 exp

🧫 AAV-LRRK2 IND-Enabling Study DesignKG

experiment · 1,843 words · 1 hyp5 ana21 exp

🧫 Sleep Disruption and Alzheimer's Disease — mechanism and interventionKG

experiment · 1,781 words · 51 hyp32 ana52 exp

🧫 Iron Dyshomeostasis in MSA Pathogenesis ExperimentKG

experiment · 1,759 words · 143 hyp52 ana7 exp

🧫 LRRK2/GBA Mutation Carrier Resilience — Why Some Carriers Never Develop PDKG

experiment · 1,715 words · 25 hyp30 ana30 exp

🧫 Basic Mechanism: Membrane-Driven Alpha-Synuclein NucleationKG

experiment · 1,666 words · 6 hyp8 ana1 exp

🧫 FXTAS Phenotypic Penetrance: Why Only 40% of FMR1 Premutation Carriers Develop FXTASKG

experiment · 1,587 words · 29 hyp21 ana4 exp

🧫 tACS Connectivity Trial in Early Alzheimer'sKG

experiment · 1,542 words · 9 hyp24 ana3 exp

🧫 Peroxisomal Dysfunction Validation in Parkinson's DiseaseKG

experiment · 1,458 words · 3 hyp17 ana65 exp

🧫 Sex Differences in Alzheimer's Disease — mechanisms and therapeutic implicationsKG

experiment · 1,448 words · 46 hyp55 ana52 exp

🧫 Senolytic Therapy (D+Q) Phase IIa Trial in Early Alzheimer's DiseaseKG

experiment · 1,389 words · 50 hyp41 ana49 exp

🧫 Epigenetic Clocks in Neurodegeneration — Causal Drivers or Passive MarkersKG

experiment · 1,363 words · 306 hyp59 ana66 exp

🧫 Astrocyte Ferritin Iron Metabolism Dysfunction in Parkinson's DiseaseKG

experiment · 1,334 words · 115 hyp66 ana70 exp

🧫 Experimental: CAAR-T Cell Therapy for Autoantibody-Mediated Neurotoxicity in ADKG

experiment · 1,317 words · 66 hyp21 ana10 exp

🧫 Alpha-Synuclein Staging and Spreading in DLB — Spatial Propagation MappingKG

experiment · 1,255 words · 8 hyp9 ana8 exp

🧫 Animal Model Comparison for Neurodegenerative Disease TherapeuticsKG

experiment · 1,246 words · 145 hyp66 ana4 exp

🧫 Sirtuin Pathway Dysfunction Validation in Parkinson's DiseaseKG

experiment · 1,232 words · 13 hyp23 ana67 exp

🧫 Viral and Post-Infectious Mechanisms in ALS — Experiment DesignKG

experiment · 1,224 words · 10 hyp47 ana25 exp

🧫 ER-Golgi Secretory Pathway Dysfunction in PD - Experiment DesignKG

experiment · 1,208 words · 7 hyp12 ana3 exp

🧫 Validation: Membrane-Nucleation in iPSC NeuronsKG

experiment · 1,199 words · 7 hyp11 ana18 exp

🧫 Microglial Aging and Immune Memory in Neurodegeneration — Training the Brain's MacrophagesKG

experiment · 1,193 words · 288 hyp57 ana63 exp

🧫 Microbiome-Gut-Brain Axis in Alzheimer's Disease — mechanism and interventionKG

experiment · 1,150 words · 38 hyp37 ana50 exp

🧫 AAV-LRRK2 Gene Therapy IND-Enabling Study DesignKG

experiment · 1,119 words · 21 hyp20 ana22 exp

🧫 Blood-Brain Barrier Aging and Neurodegeneration — From Leakage to Neuronal LossKG

experiment · 1,101 words · 325 hyp68 ana60 exp

🧫 SCFA-Mediated Neuroinflammation in Alzheimer's DiseaseKG

experiment · 1,098 words · 75 hyp29 ana61 exp

🧫 Anti-Tau Therapy Failure Mechanism in PSP — Why Clinical Trials Have Not SucceededKG

experiment · 1,093 words · 27 hyp23 ana34 exp

🧫 N-of-1 Clinical Trial Design for CBS/PSPKG

experiment · 1,076 words · 6 hyp4 ana17 exp

🧫 Anti-Tau Antibody vs ASO/Gene Therapy — Comparative Efficacy in 4R-TauopathyKG

experiment · 1,075 words · 25 hyp24 ana4 exp

🧫 Selective Neuronal Vulnerability to Aging — Mapping Why Specific Neurons DegenerateKG

experiment · 1,068 words · 86 hyp26 ana5 exp

🧫 Selective Vulnerability of Dopaminergic Neurons — Mechanism and ProtectionKG

experiment · 1,060 words · 22 hyp22 ana16 exp

Loading more wiki pages...